Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Фаза 2
Завершено
NCT02477670
| Заболевание | Schizophrenia |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 145 участн. |
|---|
| Вмешательство | AVP-786 |
|---|
| Дата начала | 1.09.2015 |
|---|
| Дата завершения | 21.07.2017 |
|---|
| Публикация результатов | 16.09.2020 |
|---|
Кратко
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Change From Baseline in the 16-Item Negative Symptom Assessment (NSA-16) Total Score at Week 6 and Week 12
Baseline and Week 6 (Stage 1); Baseline (Week 6) and Week 12 (Stage 2) · score on a scale
| Stage 1: AVP-786 | 61.0 ± 7.53 score on a scale |
|---|
| Stage 1: Placebo | 60.4 ± 7.71 score on a scale |
|---|
| Stage 1: AVP-786 | -5.0 ± 5.64 score on a scale |
|---|
| Stage 1: Placebo | -3.4 ± 5.54 score on a scale |
|---|
| Stage 1 Placebo Non-responders; Stage 2: Placebo | 57.6 ± 9.39 score on a scale |
|---|
| Stage 1 Placebo Non-responders; Stage 2: AVP-786 | 57.6 ± 9.09 score on a scale |
|---|
| p-value | 0.073 |
|---|
| SPCD Weighted OLS z-statistic | -1.79 (95% CI -3.75–0.17) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.